ASSESSMENT OF LEFT VENTRICULAR SYSTOLIC/DIASTOLIC FUNCTION BY ECHOCARDIOGRAPHY IN SEROPOSITIVE HIV OTHERWISE ASYMPTOMATIC PATIENTS
Abstract
Acquired immunodeficiency syndrome is a serious problem worldwide. Recent advances in the knowledge about human immunodeficiency virus (HIV) replication and the treatment of HIV infection has improved survival in HIV patients. Because of the longer survival in HIV patients, the more manifestations of late-stage HIV infection will be seen, including HIV-related cardiac diseases. This may take the form of either a dilated cardiomyopathy or isolated left or right ventricular dysfunction, is associated with a poor prognosis, and results in symptomatic heart failure in up to 5% of HIV patients. The precise cause of HIV-associated cardiomyopathy remains unclear but is undoubtedly complex, and most probably multifactorial. We Performed Case-Control study in 70 Seropositive asymptomatic HIV patients in SN Medical College and found LV dysfunction (diastolic and systolic dysfunction) in comparison to age and sex-matched control group. Our study aims to find the cases of undiagnosed cardiac dysfunction in asymptomatic seropositive HIV cases in the early course of illness that are not on ART at yet so that they could be further monitored for cardiac dysfunction. We found a significant difference in LVEF in cases as compared to controls.
Downloads
References
2. Corboy JR, Fink L, Miller WT. Congestive cardiomyopathy in association with AIDS. Radiology 1987, 165:139–141.
3. Stewart JM, Kaul A, Gromische DS, et al. Symptomatic cardiac dysfunction in children with human immunodeficiency virus infection. Am Heart J 1989, 117:140–144.
4. Lewis W. AIDS: cardiac findings from 115 autopsies. Prog Cardiovasc Dis 1989, 32:207–215.
5. Himelman B, Dohrmann M, Goodman P, et al. Severe pulmonary hypertension and cor pulmonale in the acquired immunodeficiency syndrome. Am J Cardiol 1989, 64:1396–1399.
6. Blanchard DG, Hagenhoff C, Chow LC, et al. Reversibility of cardiac abnormalities in human immunodeficiency virus (HIV)- infected individuals; a serial echocardiographic study. J Am Coll Cardiol 1991, 17:1270–1276.
7. Currie PF, Jacob AJ, Foreman AR, Elton RA, Brettle RP, Boon NA. Heart muscle disease related to HIV infection: prognostic implications. Br Med J 1994, 309:1605–1607.
8. De Castro S, D’Amati G, Gallo P, et al. Frequency of development of acute global left ventricular dysfunction in human immunodeficiency virus infection. J Am Coll Cardiol 1994, 24:1018–1024
9. Aretz TH, Billingham ME, Edwards WD, et al. Myocarditis: a histopathologic definition and classification. Am J Cardiovasc Pathol 1987, 1:3–14.
10. Herskowitz A, Wu TC, Willoughby S, et al. Myocarditis and cardiotropic viral infection associated with severe left ventricular dysfunction in late-stage infection with human immunodeficiency virus. J Am Coll Cardiol 1994, 24:1025–1032.
11. Clapham PR, Weber JN, Whitby D, et al. Soluble CD4 blocks the infectivity of diverse strains of HIV and SIV for T cells and monocytes but not for brain or muscle cells. Nature 1989, 337;368–370.
12. Herskowitz A, Willoughby S, Wu TC, et al. Immunopathogenesis of HIV-1 associated cardiomyopathy. Clin Immunol Immunopathol 1993, 68:234–241.
13. Ho DD, Pomerantz RJ, Kaplan JC. Pathogenesis of infection with human immunodeficiency virus. N Engl J Med 1987, 317: 278–286.
14. Rodriguez ER, Nasim S, Hsia J, et al. Cardiac monocytes and dendritic cells harbor human immunodeficiency virus in infected patients with and without cardiac dysfunction: detection by multiplex, nested, a polymerase chain reaction in individually microdissected cells from right ventricular endomyocardial biopsy tissue. Am J Cardiol 1991, 68:1511–1520.
15. Skurkovich S, Skurkovich B, Bellanti JA. A disturbance of interferon synthesis with the hyperproduction of unusual kinds of interferon can trigger autoimmune disease and play a pathogenetic role in AIDS: the removal of these interferons can be therapeutic. Med Hypotheses 1994, 42:27–35.
16. Kan H, Xie Z, Finkel MS. HIV gp120 enhances NO production by cardiac myocytes through p38 MAP kinase-mediated NFkappa _ activation. Am J Physiol Heart Circ Physiol 2000, 279:H3138–H3143.
17. Herskowitz A, Willoughby S, Wu TC, et al. Immunopathogenesis of HIV-1 associated cardiomyopathy. Clin Immunol Immunopathol 1993, 68:234–241.
18. Barbarao G, Di-Lorenzo G, Soldini M, et al. Clinical course of cardiomyopathy in HIV-infected patients with or without encephalopathy related to the myocardial expression of tumor necrosis factor-alpha and nitric oxide synthase. AIDS 2000, 14:827–838.
